The Recommended Uniform Screening Panel now includes DMD and MLD, which has implications for firms developing treatments for ...

Doug Ingram of Sarepta Therapeutics is my pick for the Worst Biopharma CEO of 2025. He was an easy selection, but unlike some ...

Investor attention has returned to Sarepta Therapeutics amid reports of the biotech firm's vigorous legal strategy to protect ...

Solid Biosciences Inc. (NASDAQ:SLDB) develops therapies for neuromuscular and cardiac diseases in the US. In addition, the ...

Average Upside Potential as of December 10: 104.08% ...

A mom was overjoyed when she learned a gene therapy treatment could save her child's life, until she found out no one would cover the $2 million price tag.

A new class of life-saving drugs is helping children who once had no hope. But some carry a price tag of millions for a ...

Analysts are intrested in these 5 stocks: ( ($VRT) ), ( ($AFRM) ), ( ($SRPT) ), ( ($MU) ) and ( ($PEP) ). Here is a breakdown of their recent ...

Once the exchange agreements close, Sarepta will have $893.4 million in debt due in 2030 following previous refinancing it announced in August.